MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/440/0.01/20.09.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/440/0.01/20.09.24 Stock

DE000ME4N3F5

Real-time Bid/Ask 09:08:04 2024-07-02 EDT
0.48 ^EUR / 0.5 ^EUR	+6.52%

Current month	-8.00%
1 month	+27.78%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/440/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	09:15am	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	08:34am	BU
Vertex to Announce Second Quarter 2024 Financial Results on August 1	07-01	BU
Verve Therapeutics, Inc. Announces Board Appointments	06-28	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-02	0.48	+4.35%
24-07-01	0.46	-8.00%
24-06-28	0.5	+2.04%
24-06-27	0.49	+2.08%
24-06-26	0.48	0.00%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 07:59 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME4N3F
ISIN	DE000ME4N3F5
Date issued	2023-12-05
Strike	440 $
Maturity	2024-09-20 (80 Days)
Parity	100 : 1
Emission price	0.16 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.6 €
Lowest since issue	0.14 €
Delta	0.71x
Omega	6.448
Premium	4.41x
Gearing	9.06x
Moneyness	1.071
Difference Strike	-31.25 $
Difference Strike %	-7.10%
Spread	0.01 €
Spread %	2.04%
Theoretical value	0.5000
Implied Volatility	38.23 %
Total Loss Probability	35.99 %
Intrinsic value	0.2912
Present value	0.2088
Break even	493.66 €
Theta	-0.01x
Vega	0.01x
Rho	0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

471.2 USD

Average target price

468.3 USD

Spread / Average Target

-0.63%

Consensus